Syndax Pharmaceuticals (SNDX) Stock Price, News & Analysis

Company Overview

Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for the treatment of cancer. Headquartered in Waltham, Massachusetts, the company focuses on small-molecule inhibitors that target key epigenetic and protein interaction pathways. Syndax’s research platform aims to enhance the effectiveness of existing therapies and address high unmet medical needs in oncology.

The company’s lead investigational candidate, entinostat, is a selective class I histone deacetylase (HDAC) inhibitor being evaluated for multiple solid tumor and hematologic indications. Entinostat is currently in Phase 3 development in combination with pembrolizumab for patients with hormone receptor-positive, HER2-negative advanced breast cancer. Syndax’s pipeline also includes SNDX-5613 (revumenib), a menin inhibitor targeting acute leukemias harboring MLL rearrangements or NPM1 mutations, which is advancing through Phase 2 clinical trials. In addition to these core programs, Syndax is exploring combination strategies to maximize clinical benefit and address resistance mechanisms.

The company was founded in 2002 and has cultivated collaborations with leading academic institutions and industry partners to accelerate development and broaden the reach of its therapies. Syndax operates primarily in the United States but plans to expand its global footprint through strategic partnerships and licensing agreements. Under the leadership of President and Chief Executive Officer Daniel A. Swisher and Chief Financial Officer Wolfgang R. Grosse, Syndax continues to build a pipeline designed to deliver meaningful improvements in outcomes for cancer patients worldwide.

Key Stats

• Today's Range: $18.64 to $19.50
• 50-Day Range: $16.96 to $24.84
• 52-Week Range: $9.49 to $25.59
• Volume: 1.21 million shs
• Average Volume: 1.54 million shs
• Market Capitalization: $1.69 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $42.55
• Consensus Rating: Moderate Buy

Syndax Pharmaceuticals Stock Analysis - MarketRank™

Syndax Pharmaceuticals scored higher than 60% of companies evaluated by MarketBeat, and ranked 385th out of 898 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.1 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Syndax Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.92, and is based on 1 strong buy rating, 11 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Syndax Pharmaceuticals has a consensus price target of $42.55, representing about 123.3% upside from its current price of $19.05.

Amount of Analyst Coverage

Syndax Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Syndax Pharmaceuticals are expected to grow in the coming year, from ($1.65) to ($0.45) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Syndax Pharmaceuticals is -6.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Syndax Pharmaceuticals is -6.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Syndax Pharmaceuticals has a P/B Ratio of 25.74. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

24.68% of the float of Syndax Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Syndax Pharmaceuticals has a short interest ratio ("days to cover") of 9.83.

Change versus previous month

Short interest in Syndax Pharmaceuticals has recently decreased by 4.57%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Syndax Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Syndax Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 3.2 / 5
• News Sentiment: 1.13

News Sentiment

Syndax Pharmaceuticals has a news sentiment score of 1.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.91 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 9 news articles for Syndax Pharmaceuticals this week, compared to 5 articles on an average week.

Search Interest

Only 1 people have searched for SNDX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.9 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Syndax Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,120,789.00 in company stock.

Percentage Held by Insiders

4.80% of the stock of Syndax Pharmaceuticals is held by insiders.

Percentage Held by Institutions

Syndax Pharmaceuticals has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 4/30/2026
• Today: 8/01/2026
• Next Earnings (Estimated): 8/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:SNDX
• CIK: 1395937
• Web: www.syndax.com
• Phone: (781) 419-1400
• Fax: 781-419-1420
• Employees: 110
• Year Founded: 2005

Price Target and Rating

• Average Price Target for Syndax Pharmaceuticals: $42.55
• High Price Target: $57.00
• Low Price Target: $34.00
• Potential Upside/Downside: +123.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.92
• Research Coverage: 13 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.79)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$285.42 million
• Net Margins: -111.88%
• Pretax Margin: -111.88%
• Return on Equity: -256.65%
• Return on Assets: -45.25%

Debt

• Debt-to-Equity Ratio: 8.26
• Current Ratio: 5.47
• Quick Ratio: 5.06

Sales & Book Value

• Annual Sales: $172.35 million
• Price / Sales: 9.79
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.74 per share
• Price / Book: 25.74

Miscellaneous

• Outstanding Shares: 88,610,000
• Free Float: 84,357,000
• Market Cap: $1.69 billion
• Optionable: Optionable
• Beta: 0.37